文献速递核素与放射性配体治疗放射性药物与辐射防护

188Re脂质体在转移性肿瘤患者中的0期药代动力学、生物分布与剂量学研究

A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors.
PubMed 文献 · EJNMMI Res · 2019-05-22

这项0期低放射性活度临床试验纳入12例转移性肿瘤患者,静脉注射111 MBq的188Re脂质体后于1、4、8、24、48、72小时行全身扫描与SPECT/CT,并用VelocityAI和OLINDA/EXM软件评估肿瘤靶向性、药代动力学、生物分布、剂量学与安全性。结果显示188Re脂质体在血液和血浆中的T½z分别为36.73±14.00 h和52.02±45.21 h,主要器官吸收剂量远低于参考最大耐受剂量,部分患者出现治疗反应,支持进一步开展剂量递增的1期临床试验。

要点

  • 188Re脂质体在血液与血浆中的T½z分别为36.73±14.00 h和52.02±45.21 h。
  • 肝、脾、肺、肾、骨髓吸收剂量分别为0.92±0.35、1.38±1.81、0.58±0.28、0.32±0.09、0.06±0.01 mGy/MBq。
  • 部分患者出现治疗反应,作者认为结果支持开展剂量递增1期试验。

核心结论

  • 188Re脂质体在部分癌症患者中实现较好的肿瘤蓄积和肿瘤与正常器官摄取比,其药代动力学、生物分布与剂量学结果支持进一步开展剂量递增的1期临床试验。

研究设计与样本

  • 0期低放射性活度探索性新药临床试验,纳入12例转移性肿瘤患者。
  • 静脉注射111 MBq的188Re脂质体,注射后1、4、8、24、48、72小时行系列全身扫描与SPECT/CT。
  • 使用VelocityAI和OLINDA/EXM软件评估肿瘤靶向性、药代动力学、生物分布、剂量学与安全性,并采集不同时间点血样监测肝、肾及血液学功能变化。

主要发现

  • 188Re脂质体在血液和血浆中的T½z分别为36.73±14.00 h和52.02±45.21 h。
  • 肝、脾、肺、肾、骨髓的吸收剂量分别为0.92±0.35、1.38±1.81、0.58±0.28、0.32±0.09、0.06±0.01 mGy/MBq,远低于注射188Re脂质体后的参考最大耐受剂量。
  • 188Re脂质体被转移性肿瘤病灶和正常网状内皮系统摄取,部分患者表现出治疗反应。

关键数值与推荐

  • 试验注册号为台湾FDA MA1101G0(2012年1月31日)。
  • 注射活度为111 MBq的188Re脂质体,扫描时间点为注射后1、4、8、24、48、72小时。
  • 血液T½z为36.73±14.00 h,血浆T½z为52.02±45.21 h;肝、脾、肺、肾、骨髓吸收剂量依次为0.92±0.35、1.38±1.81、0.58±0.28、0.32±0.09、0.06±0.01 mGy/MBq。

临床怎么用

  • 作为0期探索性研究,结果可用于支持后续剂量递增1期临床试验的设计。
  • 188Re脂质体可被转移性肿瘤病灶和网状内皮系统摄取,评估时需关注肝、脾等RES器官的摄取与剂量。
  • 研究中肝、脾、肺、肾、骨髓吸收剂量远低于参考最大耐受剂量,安全性监测涵盖肝、肾及血液学功能。

局限性

  • 原文未报告样本量以外的入组人群特征、肿瘤类型分布与具体疗效评价标准。
  • 原文未报告统计比较、P值及剂量递增方案细节。
  • 原文未报告长期随访安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) demonstrates favorable in vivo tumor targeting, biodistribution, pharmacokinetics, and dosimetry. It inhibits the growth of tumors, increased survival, demonstrates good synergistic combination, and was safe to use. This study conducts a phase 0 low-radioactivity clinical trial of nano-targeted radiotherapeutics 188Re-liposome to evaluate the effectiveness with which it targets tumors and the pharmacokinetics, biodistribution, dosimetry, and its safety in use. Twelve patients with metastatic cancers are studied in this trial. Serial whole-body scans and SPECT/CT are taken at 1, 4, 8, 24, 48, and 72 h after intravenous injection of 111 MBq of 188Re-liposome. The effectiveness with which tumors are targeted, the pharmacokinetics, biodistribution, dosimetry, and safety are evaluated using the VelocityAI and OLINDA/EXM software. Blood samples are collected at different time points for a pharmacokinetics study and a safety evaluation that involves monitoring changes in liver, renal, and hematological functions. RESULTS: The T½z for 188Re-liposome in blood and plasma are 36.73 ± 14.00 h and 52.02 ± 45.21 h, respectively. The doses of radiation that are absorbed to vital organs such as the liver, spleen, lung, kidney, and bone marrow are 0.92 ± 0.35, 1.38 ± 1.81, 0.58 ± 0.28, 0.32 ± 0.09, and 0.06 ± 0.01 mGy/MBq, respectively, which is far less than the reference maximum tolerance dose after injection of 188Re-liposome. 188Re-liposome is absorbed by metastatic tumor lesions and the normal reticuloendothelial (RES) system. Certain patients exhibit a therapeutic response. CONCLUSION: This phase 0 exploratory IND study shows that nanocarrier 188Re-liposome achieves favorable tumor accumulation and tumor to normal organ uptake ratios for a subset of cancer patients. The clinical pharmacokinetic, biodistribution, and dosimetry results justify a further dose-escalating phase 1 clinical trial. TRIAL REGISTRATION: Taiwan FDA MA1101G0 (Jan 31, 2012).

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Wang SJ, Huang WS, Chuang CM, et al. A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. EJNMMI Res. 2019. PMID: 31119414. doi:10.1186/s13550-019-0509-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。